Aeglea BioTherapeutics, Inc.

Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy Designation…More. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline.